Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lora Cooper-Yoakum

Nurse Practitioner, Critical Care Medicine Knoxville, TN Nurse Practitioner

NPI 1689092751 CMS profile 10816792

1924 Alcoa Hwy, Knoxville, TN 37920

Open in the dashboard

General payments

$18,077

877 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lora Cooper-Yoakum of Knoxville, TN is reported in the CMS Open Payments database as having received $18,077 across 877 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,706 184
2024 General $4,573 218
2023 General $3,374 186
2022 General $3,807 190
2021 General $1,618 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lora Cooper-Yoakum
  • Nurse Practitioner, Critical Care Medicine median
  • Middle half of Nurse Practitioner, Critical Care Medicine
  • National median

In program year 2025, general payments to Lora Cooper-Yoakum were reported at $4,706. Among 524 Nurse Practitioner, Critical Care Medicine profiles paid that year, the median was $119 and the middle half received between $34 and $300.

Show as a table
Year Lora Cooper-Yoakum Nurse Practitioner, Critical Care Medicine median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,618 $103 $27–$237 $132
2022 $3,807 $125 $44–$255 $149
2023 $3,374 $116 $32–$261 $160
2024 $4,573 $122 $32–$292 $164
2025 $4,706 $119 $34–$300 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,941 257 payments
  2. Amgen Inc. $3,538 170 payments
  3. UCB, Inc. $1,648 84 payments
  4. AstraZeneca Pharmaceuticals LP $1,126 51 payments
  5. E.R. Squibb & Sons, L.L.C. $1,066 20 payments
  6. GlaxoSmithKline, LLC. $836 53 payments
  7. Lilly USA, LLC $831 37 payments
  8. Janssen Biotech, Inc. $830 28 payments
  9. Genzyme Corporation $620 18 payments
  10. Horizon Therapeutics plc $496 19 payments
  11. Other $3,145 140 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,859 869 payments
  2. Consulting Fee $736 1 payment
  3. Education $482 7 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $3,446 226 payments
  2. Otezla $1,316 74 payments
  3. Cimzia $1,076 62 payments
  4. SAPHNELO $1,016 47 payments
  5. Enbrel Inflammation $966 53 payments
  6. BENLYSTA $836 53 payments
  7. TREMFYA $768 25 payments
  8. Enbrel Inflammation $762 40 payments
  9. KEVZARA $745 21 payments
  10. TALTZ $735 35 payments
  11. Other $7,515 366 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,116

Median for Nurse Practitioner: 389

Drug cost

$1,158,731

Median for Nurse Practitioner: $21,885

Branded share of claims

26.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 48 $355,811
Humira(Cf) Pen Adalimumab Brand 37 $281,872
Rinvoq Upadacitinib Brand 34 $268,936
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $127,606
Orencia Abatacept Brand 13 $71,975
Hydroxychloroquine Sulfate Generic 403 $17,320
Methotrexate Methotrexate Sodium Brand 352 $9,612
Leflunomide Generic 95 $7,057
Sulfasalazine Dr Sulfasalazine Brand 61 $2,492
Prednisone Generic 302 $2,266

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$72,393

Of which drugs: $321

Medicare patients

336

Average age 70

Services billed

5,745

250 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Depression 32%
Diabetes 29%
Osteoporosis 26%
Chronic kidney disease 22%
Ischemic heart disease 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 1,880 $177

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$982 34 —
Enbrel
$330 48 —
SAPHNELO
$324 — —
Cimzia
$258 — —
SKYRIZI
$226 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

877 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Critical Care Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record